Potent in Vitro and In Vivo Efficacy of BYON4413, a Duba-Based Antibody-Drug Conjugate Targeting CD123 in Acute Myeloid Leukemia

被引：3
|
作者：
van der Lee, Miranda [1 ]
van Achtenberg, Tanja [1 ]
Brouwers-Vos, Annet [2 ]
van der Vleuten, Monique [1 ]
Kappers, Wendy [1 ]
Verheijden, Gijs [1 ]
Huls, Geert A. [3 ]
van Wigcheren, Glenn [1 ]
Ubink, Ruud [1 ]
Sesink, Aloys [1 ]
MacInnes, Alyson [1 ]
Schuringa, Jan Jacob [4 ]
Dokter, Wim [1 ]
机构：
[1] Byondis BV, Nijmegen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[3] Univ Med Ctr Groningen, Groningen, Netherlands
[4] Univ Med Ctr Groningen, Dept Expt Hematol, Groningen, Netherlands
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-177622
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Anti-Leukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody-Conjugate in Acute Myeloid Leukemia
    Han, Lina
    Rowinsky, Eric
    Brooks, Christopher
    Zal, Tomasz
    Zal, M. Anna
    Burks, Jared K.
    Zhou, Jin
    Ciurea, Stefan O.
    Alatrash, Gheath
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Andreeff, Michael
    Ravandi, Farhad
    Konopleva, Marina
    BLOOD, 2014, 124 (21)
  • [42] The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia
    Egan, Pamela C.
    Reagan, John L.
    ONCOTARGETS AND THERAPY, 2018, 11 : 8265 - 8272
  • [43] In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia
    Hagemann, Urs B.
    Wickstroem, Katrine
    Wang, Ellen
    Shea, Adam O.
    Sponheim, Kristine
    Karlsson, Jenny
    Bjerke, Roger M.
    Ryan, Olav B.
    Cuthbertson, Alan S.
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (10) : 2422 - 2431
  • [44] ATG-022, an antibody-drug conjugate targeting Claudin 18.2, demonstrated potent in vivo efficacy in gastric cancer patient-derived xenografts
    Chen, Peng
    Liu, Yun
    Deng, Min
    Tian, Linjie
    Lynch, Kevin
    Shan, Bo
    Mei, Jay
    Hou, Bing
    CANCER RESEARCH, 2022, 82 (12)
  • [45] CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate
    Kirkey, Danielle C.
    Blankenfeld, Melia
    Hylkema, Tiffany
    Loo, Deryk
    Ward, Ashley
    Robinson, Leila
    Peplinski, Jack H.
    Wallace, Logan K.
    Pardo, Laura
    Menssen, Andrew J.
    Ries, Rhonda E.
    Meshinchi, Soheil
    BLOOD, 2023, 142
  • [46] A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.
    Daver, Naval Guastad
    Montesinos, Pau
    DeAngelo, Daniel J.
    Wang, Eunice S.
    Todisco, Elisabetta
    Tarella, Corrado
    Martinelli, Giovanni
    Erba, Harry Paul
    Deconinck, Eric
    Sweet, Kendra L.
    Walter, Roland B.
    Levy, Moshe Yair
    Pemmaraju, Naveen
    Lane, Andrew A.
    Rizzieri, David
    Konopleva, Marina
    Sloss, Callum Mortimer
    Wang, Jiuzhou
    Malcolm, Kara E.
    Zweidler-McKay, Patrick A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Potent Activity of Duocarmyin- and Mmaf-Conjugated FLT3-Directed Antibody-Drug Conjugates Towards Acute Myeloid Leukemia Stem Cells in Vitro and In Vivo
    Able, Marina
    Kasper, Marc-Andre
    Vick, Binje
    Schwach, Jonathan
    Gao, Xiang
    Schmitt, Saskia
    Tizazu, Belay
    Fischer, Amrei
    Kuenzl, Sarah
    Leilich, Marit
    Mai, Isabelle
    Ochtrop, Philipp
    Stengl, Andreas
    de Geus, Mark A. R.
    von Bergwelt-Baildon, Michael
    Schumacher, Dominik
    Helma, Jonas
    Goetze, Katharina S. S.
    Jeremias, Irmela
    Feuring, Michaela
    Spiekermann, Karsten
    BLOOD, 2024, 144 : 1392 - 1393
  • [48] IMGN632: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) OF A CD123-TARGETING ANTIBODY WITH A POTENT DNA-ALKYLATOR IS HIGHLY ACTIVE IN PRECLINICAL MODELS OF AML WITH POOR PROGNOSIS
    Kovtun, Y.
    Jones, G.
    Harvey, L.
    Rui, L.
    Audette, C.
    Liu, F.
    Bai, C.
    Wilhelm, A.
    Yoder, N. C.
    Adams, S.
    Goldmacher, V. S.
    Chari, R.
    Chittenden, T.
    HAEMATOLOGICA, 2016, 101 : 222 - 222
  • [49] Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
    Daver, Naval G.
    Montesinos, Pau
    DeAngelo, Daniel J.
    Wang, Eunice S.
    Papadantonakis, Nikolaos
    Deconinck, Eric
    Erba, Harry P.
    Pemmaraju, Naveen
    Lane, Andrew A.
    Rizzieri, David A.
    Sweet, Kendra L.
    Martinelli, Giovanni
    Tarella, Corrado
    Todisco, Elisabetta
    Konopleva, Marina Y.
    Sloss, Callum M.
    Culm-Merdek, Kerry
    Zweidler-McKay, Patrick A.
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
  • [50] A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies
    Daver, Naval G.
    Erba, Harry P.
    Papadantonakis, Nikolaos
    DeAngelo, Daniel J.
    Wang, Eunice S.
    Konopleva, Marina Y.
    Sloss, Callum M.
    Culm-Merdek, Kerry
    Zweidler-McKay, Patrick A.
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
12345